Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
about
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacinDo we need an intravenous fluoroquinolone?Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centersComparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance.In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.Comparative activities of eight quinolones against members of the Bacteroides fragilis group.Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteriaIn vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocciBactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.Levofloxacin and sparfloxacin: new quinolone antibiotics.Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
P2860
Q24616126-DF9067C7-CCFA-4133-B97A-4465663AD3CBQ33606570-5C76597D-60C1-4286-807F-711D2C673836Q33666710-FD6490ED-859D-483E-8EAA-4DBB9CD41B59Q33696254-E18952AB-6BB6-46A4-92FD-469FFDEBF9D4Q33751682-8D7330BC-03A4-41A4-B03D-CE5E51025AB6Q33771929-7FBD9950-7172-47A7-B3A9-A8E4940A099FQ35118711-EDD55CBF-EE23-4714-9735-FA926EAA37C8Q35123325-76A0DE93-442C-425A-856C-845ADE542182Q35125320-2DF4D56C-56A9-41AA-8B05-5DC1E6874C9DQ35809411-B5290825-8064-4ADD-913E-CBE051331BAFQ35821986-59D6D981-893D-48E1-A6D2-C54B73E436E8Q35836848-B0B9EBE5-24CB-485B-9EBC-159041F9B6F3Q35846160-679BC6F7-C4DF-46A0-9388-29CD0B0A877DQ35862887-B8989632-E726-4E2C-9F36-6C25278F997FQ35900278-1BB2D388-9756-458E-A53B-EB2A61AA8194Q36517786-A43820B0-1317-4352-B256-A2B7E314A8C0Q37881273-C8896A2F-8BC4-4AD1-A488-8788FABE2B33Q39471785-E10106DD-BB36-46C1-8A06-44F7ADD918E2Q39558630-78E32658-3E2A-419D-AF59-D46E259932E0
P2860
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Multicenter evaluation of the ...... 2 clinical bacterial isolates.
@en
type
label
Multicenter evaluation of the ...... 2 clinical bacterial isolates.
@en
prefLabel
Multicenter evaluation of the ...... 2 clinical bacterial isolates.
@en
P2093
P2860
P356
P1476
Multicenter evaluation of the ...... 2 clinical bacterial isolates.
@en
P2093
E H Gerlach
M A Pfaller
P2860
P304
P356
10.1128/AAC.35.4.764
P407
P577
1991-04-01T00:00:00Z